Table 1.

Ongoing trials for patients with HPV-positive HNC.

ClinicalTrials.gov identifier	# of patients	Group/institution	Trial Design
NCT01084083	83*	ECOG	Phase 2: neoadjuvant chemo and response adapted radiation (54 or 66–70 Gy) + cetuximab
NCT01525927	50	North Shore Long Island Jewish Health System	Phase 2: neoadjuvant TPF and response adapted RT (60 Gy) +/− concurrent chemo
NCT01716195	50	Univ. of California Davis	Phase 2: neoadjuvant chemo followed by paclitaxel + response adapted RT (50 or 60 Gy)
NCT01663259	36	Univ. of Michigan	Phase 2: weekly cetux + RT (70 Gy)
NCT01530997	40	Univ. of North Carolina	Phase 2: radiation with weekly cisplatin followed by supra- selective neck dissection
pending	337	ECOG	Phase 2: transoral resection - risk adapted postop RT (0 vs. 50 vs. 60 vs. 66Gy with weekly cisplatin)
NCT01302834	706	RTOG	Phase 3: randomized to cetuximab vs. cisplatin with concurrent RT (70 Gy in 6 weeks)
NCT01874171	304	University of Warwick	Phase 3: randomized to cetuximab vs. cisplatin with concurrent RT (70 Gy in 7 weeks)
NCT01706939	365	Mount Sinai School of Medicine	Phase 3: weekly carbo/cetuximab + 56 Gy vs. weekly carbo + 70 Gy
NCT01687413	496	Washington Univ.	Phase 3: postop RT (60 Gy) +/− weekly cisplatin

RTOG: Radiation Therapy Oncology Group; ECOG: Eastern Cooperative Oncology Group; RT: Radiation therapy

^*trial closed to accrual